|
| Press Releases |
|
 |
|
| Friday, March 13, 2026 |
|
|
CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream (Lumirix(R)) Achieves Initial Prescriptions in Multiple Regions in China for Patients with Vitiligo |
| On 12 March 2026, China Medical System Holdings Limited is pleased to announce that its subsidiary, Dermavon Holdings Limited has its innovative prescription medicine ruxolitinib phosphate cream (Lumirix(R)) (the "Product", marketed as Opzelura(R) in the U.S., Europe and Canada) recorded the initial prescriptions for vitiligo patients across 30 provincial-level regions. more info >> |
|
| Thursday, March 5, 2026 |
|
|
CMS (867.HK/8A8.SG): Self-Developed INHBE-Targeting siRNA Drug Received IND Approval for Overweight/Obesity |
| China Medical System Holdings Limited ("CMS" or the "Group") is pleased to announce that self-developed innovative drug INHBE-targeting small nucleic acid drug CMS-D008 injection ("CMS-D008") received the Drug Clinical Trial Approval Notice issued by National Medical Products Administration ("NMPA") on 4 March 2026. more info >> |
|
| Tuesday, February 24, 2026 |
|
|
CMS (867.HK/8A8.SG): NDA for Additional Indication Atopic Dermatitis (AD) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China |
| CMS (867.HK/8A8.SG): NDA for Additional Indication Atopic Dermatitis (AD) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China more info >> |
|
| Friday, January 30, 2026 |
|
|
CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Obtained China NDA Approval, Becoming The First and Only Targeted Drug for Vitiligo in China |
| CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Obtained China NDA Approval, Becoming The First and Only Targeted Drug for Vitiligo in China more info >> |
|
| Wednesday, July 16, 2025 |
|
|
A New Chapter Begins! CMS Achieves Secondary Listing on the Singapore Exchange Main Board Today |
| On the morning of 15 July 2025, China Medical System Holdings Limited ("CMS" or the "Group") rang the ceremonial bell to mark its official listing on the Singapore Exchange Main Board (Stock Abbreviation: CMS, Stock Code: 8A8). more info >> |
|
| Wednesday, June 25, 2025 |
|
|
China Medical System Holdings Limited: Proposed Secondary Listing on the Singapore Exchange |
| more info >> |
|
| Friday, March 21, 2025 |
|
|
China Medical System (00867) Released its 2024 Annual Results: Focusing on Innovation and Specialty Breakthroughs to Reshape Growth Momentum |
| On March 17, China Medical System Holdings Limited ("CMS" or the "Company") released its 2024 annual results. The Company recorded a turnover of RMB7,469 million, representing a year-on-year decrease of 6.8%; in the case that all medicines were directly sold by the Company, the turnover would be RMB8,622 million, representing a year-on-year decrease of 9.0%. more info >> |
|
| Friday, February 14, 2025 |
|
|
China Medical System (867.HK) is Included in the S&P Global Sustainability Yearbook 2025 |
| In February 11th 2025, with a Corporate Sustainability Assessment (CSA) score of 61, surpassing 93% of global peers, China Medical System Holdings Limited ("CMS" or the "Group") has been included in the S&P Global Sustainability Yearbook 2025 (the "Yearbook 2025"). more info >> |
|
| Friday, January 24, 2025 |
|
|
China Medical System (00867) Obtained Class 1 Innovative Drug Long-acting Anti-IL-4Ra Monoclonal Antibody MG-K10 |
| China Medical System (00867) Obtained Class 1 Innovative Drug Long-acting Anti-IL-4Ra Monoclonal Antibody MG-K10 more info >> |
|
| Thursday, January 9, 2025 |
|
|
China Medical System (00867) Obtained New Drug ZUNVEYL for the Treatment of Mild-to-Moderate Dementia of the Alzheimer's Type |
| China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on 8 January 2025, the Group through a wholly-owned subsidiary of the Company entered into a License, Collaboration and Distribution Agreement (the "Agreement") with Alpha Cognition Inc. ("Alpha") of the improved new drug ZUNVEYL (benzgalantamine delayed-release tablets)("ZUNVEY" or the "Product") for the treatment of mild-to-moderate dementia of the Alzheimer's type. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
U.S. Polo Assn. Unveils 2026 Spring-Summer Global Collection, Inspired by Coastal Charleston, South Carolina
Mar 19, 2026 19:00 HKT/SGT
|
|
|
Honda to Expand Motorcycle Production Capacity in India by Adding New Motorcycle Production Line to its Second Plant
Mar 19, 2026 18:32 JST
|
|
|
Honda WN7 Electric Motorcycle Wins Gold Award at iF DESIGN AWARD 2026
Mar 19, 2026 18:16 JST
|
|
|
Hitachi, The University of Technology Sydney and NTT DATA Sign MoU to Accelerate Green Transformation in Australia
Mar 19, 2026 18:08 JST
|
|
|
Affiliate of Pacific Avenue Capital Partners Completes Acquisition of Care.com from IAC
Mar 19, 2026 15:15 HKT/SGT
|
|
|
MHI Thermal Systems Expands Lineup of Air-to-Water Heat Pumps for the European Market
Mar 19, 2026 15:14 JST
|
|
|
DENSO Invests in Next Core Technologies to Enhance Performance of Electric Vehicles
Mar 19, 2026 14:25 JST
|
|
|
NEC Completes Design of Equipment for Technology Demonstration Satellite Aimed at Creating Japan's First Optical Communication Satellite Constellation
Mar 19, 2026 11:05 JST
|
|
|
Eisai: Regarding Discontinuation of Administration of "Tazverik(R) Tablets 200mg" (tazemetostat hydrobromide)
Mar 19, 2026 10:54 JST
|
|
|
Hitachi is recognized as one of the World's Most Ethical Companies(R) for a second consecutive year
Mar 19, 2026 10:41 JST
|
|
|
Aleen Inc. Insights: Exploring LOINC Standard to Enhance Wellness Data Consistency
Mar 18, 2026 23:40 HKT/SGT
|
|
|
Illuminance announces global expansion and launch of its international platform
Mar 18, 2026 23:20 HKT/SGT
|
|
|
COSCO SHIPPING Ports Announces 2025 Annual Results
Mar 18, 2026 18:36 HKT/SGT
|
|
|
HKTDC launches GreenBiz HK campaign in Bangkok
Mar 18, 2026 18:30 HKT/SGT
|
|
|
Sunshine Insurance Delivers 2025 Results: Customer Operation System Continues to Innovate
Mar 18, 2026 17:40 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
